{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:18:25Z","timestamp":1790936305203,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T00:00:00Z","timestamp":1525478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T00:00:00Z","timestamp":1525478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["EY015130"],"award-info":[{"award-number":["EY015130"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["EY017011"],"award-info":[{"award-number":["EY017011"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["EY024234"],"award-info":[{"award-number":["EY024234"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["EY014800"],"award-info":[{"award-number":["EY014800"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK058702"],"award-info":[{"award-number":["DK058702"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL128119"],"award-info":[{"award-number":["HL128119"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Angiogenesis"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s10456-018-9618-5","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T07:24:46Z","timestamp":1525505086000},"page":"751-764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy"],"prefix":"10.1007","volume":"21","author":[{"given":"Aaron B.","family":"Simmons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin A.","family":"Bretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassem","family":"Hajj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carson","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thipparat","family":"Suwanmanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Kafri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Elizabeth","family":"Hartnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,5]]},"reference":[{"key":"9618_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.visres.2017.07.006","volume":"139","author":"ME Hartnett","year":"2017","unstructured":"Hartnett ME, Baehr W, Le YZ (2017) Diabetic retinopathy, an overview. Vision Res 139:1\u20136. \n                    https:\/\/doi.org\/10.1016\/j.visres.2017.07.006","journal-title":"Vision Res"},{"key":"9618_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.12.019","author":"DF Martin","year":"2018","unstructured":"Martin DF (2018) Evolution of intravitreal therapy for retinal diseases\u2014from CMV to CNV: the LXXIV Edward Jackson Memorial Lecture. Am J Ophthalmol. \n                    https:\/\/doi.org\/10.1016\/j.ajo.2017.12.019","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"9618_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/dcr.0000000000000966","volume":"61","author":"NN Baxter","year":"2018","unstructured":"Baxter NN, Fischer HD, Richardson DP, Urbach DR, Bell CM, Rochon P, Brade A, Earle CC (2018) A population-based study of complications after colorectal surgery in patients who have received bevacizumab. Dis Colon Rectum 61(3):306\u2013313. \n                    https:\/\/doi.org\/10.1097\/dcr.0000000000000966","journal-title":"Dis Colon Rectum"},{"key":"9618_CR4","doi-asserted-by":"publisher","DOI":"10.22608\/apo.2017495","author":"MA Zarbin","year":"2018","unstructured":"Zarbin MA (2018) Anti-VEGF agents and the risk of arteriothrombotic events. Asia-Pac J Ophthalmol (Philadelphia, Pa). \n                    https:\/\/doi.org\/10.22608\/apo.2017495","journal-title":"Asia-Pac J Ophthalmol (Philadelphia, Pa)"},{"key":"9618_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2777-9","author":"M Karsy","year":"2018","unstructured":"Karsy M, Yoon N, Boettcher L, Jensen R, Shah L, MacDonald J, Menacho ST (2018) Surgical treatment of glioblastoma in the elderly: the impact of complications. J Neuro-Oncol. \n                    https:\/\/doi.org\/10.1007\/s11060-018-2777-9","journal-title":"J Neuro-Oncol"},{"issue":"5","key":"9618_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","volume":"124","author":"DK VanderVeen","year":"2017","unstructured":"VanderVeen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR (2017) Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the american academy of ophthalmology. Ophthalmology 124(5):619\u2013633. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2016.12.025","journal-title":"Ophthalmology"},{"issue":"4","key":"9618_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4161\/org.4.4.7415","volume":"4","author":"JJ Haigh","year":"2008","unstructured":"Haigh JJ (2008) Role of VEGF in organogenesis. Organogenesis 4(4):247\u2013256","journal-title":"Organogenesis"},{"issue":"7","key":"9618_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal Bevacizumab for Stage 3 + retinopathy of prematurity. N Engl J Med 364(7):603\u2013615","journal-title":"N Engl J Med"},{"issue":"6","key":"9618_CR9","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","volume":"135","author":"DK Wallace","year":"2017","unstructured":"Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, Rogers DL, Yang MB, Haider KM, VanderVeen DK, Siatkowski RM, Dean TW, Beck RW, Repka MX, Smith LE, Good WV, Hartnett ME, Kong L, Holmes JM (2017) Assessment of lower doses of intravitreous Bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol 135(6):654\u2013656. \n                    https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.1055","journal-title":"JAMA Ophthalmol"},{"key":"9618_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.4838","author":"A Stahl","year":"2018","unstructured":"Stahl A, Krohne TU, Eter N, Oberacher-Velten I, Guthoff R, Meltendorf S, Ehrt O, Aisenbrey S, Roider J, Gerding H, Jandeck C, Smith LEH, Walz JM (2018) Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr. \n                    https:\/\/doi.org\/10.1001\/jamapediatrics.2017.4838","journal-title":"JAMA Pediatr"},{"issue":"4","key":"9618_CR11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","volume":"35","author":"SN Chen","year":"2015","unstructured":"Chen SN, Lian I, Hwang YC, Chen YH, Chang YC, Lee KH, Chuang CC, Wu WC (2015) Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina 35(4):667\u2013674. \n                    https:\/\/doi.org\/10.1097\/IAE.0000000000000380","journal-title":"Retina"},{"key":"9618_CR12","first-page":"576","volume":"34","author":"JS Penn","year":"1993","unstructured":"Penn JS, Tolman BL, Lowery LA (1993) Variable oxygen exposure causes preretinal neovascularisation in the newborn rat. Invest Ophthalmol Vis Sci 34:576\u2013585","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9618_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3109\/02713689608995831","volume":"15","author":"JM Holmes","year":"1996","unstructured":"Holmes JM, Duffner LA (1996) The effect of postnatal growth retardation on abnormal neovascularization in the oxygen exposed neonatal rat. Curr Eye Res 15:403\u2013409","journal-title":"Curr Eye Res"},{"issue":"3","key":"9618_CR14","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ajpath.2011.11.031","volume":"180","author":"H Wang","year":"2012","unstructured":"Wang H, Byfield G, Jiang Y, Smith GW, McCloskey M, Hartnett ME (2012) VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression. Am J Pathol 180(3):1243\u20131253. \n                    https:\/\/doi.org\/10.1016\/j.ajpath.2011.11.031","journal-title":"Am J Pathol"},{"issue":"1","key":"9618_CR15","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/s41598-018-20278-4","volume":"8","author":"S Becker","year":"2018","unstructured":"Becker S, Wang H, Simmons AB, Suwanmanee T, Stoddard GJ, Kafri T, Hartnett ME (2018) Targeted knockdown of overexpressed VEGFA or VEGF164 in Muller cells maintains retinal function by triggering different signaling mechanisms. Sci Rep 8(1):2003. \n                    https:\/\/doi.org\/10.1038\/s41598-018-20278-4","journal-title":"Sci Rep"},{"issue":"11","key":"9618_CR16","doi-asserted-by":"publisher","first-page":"e3554","DOI":"10.1371\/journal.pone.0003554","volume":"3","author":"M Saint-Geniez","year":"2008","unstructured":"Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D\u2019Amore PA (2008) Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS ONE 3(11):e3554. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0003554","journal-title":"PLoS ONE"},{"key":"9618_CR17","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/nm1095-1024","volume":"1","author":"T Alon","year":"1995","unstructured":"Alon T, Hemo I, Itin A, Peer J, Stone J, Keshet E (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024\u20131028","journal-title":"Nat Med"},{"key":"9618_CR18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/380435a0","volume":"380","author":"P Carmeliet","year":"1996","unstructured":"Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435\u2013439","journal-title":"Nature"},{"issue":"6573","key":"9618_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/380439a0","volume":"380","author":"N Ferrara","year":"1996","unstructured":"Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O\u2019Shea KS, Powell-Braxton L, Hillan KJ, Moore MW (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380(6573):439\u2013442. \n                    https:\/\/doi.org\/10.1038\/380439a0","journal-title":"Nature"},{"issue":"6535","key":"9618_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/376062a0","volume":"376","author":"F Shalaby","year":"1995","unstructured":"Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376(6535):62\u201366. \n                    https:\/\/doi.org\/10.1038\/376062a0","journal-title":"Nature"},{"issue":"3","key":"9618_CR21","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.ajpath.2013.05.011","volume":"183","author":"H Wang","year":"2013","unstructured":"Wang H, Smith GW, Yang Z, Jiang Y, McCloskey M, Greenberg K, Geisen P, Culp WD, Flannery J, Kafri T, Hammond S, Hartnett ME (2013) Short hairpin RNA-mediated knockdown of VEGFA in Muller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity. Am J Pathol 183(3):964\u2013974. \n                    https:\/\/doi.org\/10.1016\/j.ajpath.2013.05.011","journal-title":"Am J Pathol"},{"issue":"9","key":"9618_CR22","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/mt.2008.144","volume":"16","author":"JC Giering","year":"2008","unstructured":"Giering JC, Grimm D, Storm TA, Kay MA (2008) Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 16(9):1630\u20131636. \n                    https:\/\/doi.org\/10.1038\/mt.2008.144","journal-title":"Mol Ther"},{"issue":"1","key":"9618_CR23","doi-asserted-by":"publisher","first-page":"e7475","DOI":"10.1111\/j.1755-3768.2012.02469.x","volume":"91","author":"R Hoerster","year":"2013","unstructured":"Hoerster R, Muether P, Dahlke C, Mehler K, Oberthur A, Kirchhof B, Fauser S (2013) Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol 91(1):e74\u2013e75. \n                    https:\/\/doi.org\/10.1111\/j.1755-3768.2012.02469.x","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"9618_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, Kusaka S (2012) Serum concentrations of Bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153(2):327\u2013333","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"9618_CR25","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1167\/iovs.13-11625","volume":"54","author":"M McCloskey","year":"2013","unstructured":"McCloskey M, Wang H, Jiang Y, Smith GW, Strange J, Hartnett ME (2013) Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 54(3):2020\u20132026. \n                    https:\/\/doi.org\/10.1167\/iovs.13-11625","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9618_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.12.023","author":"Z Yang","year":"2014","unstructured":"Yang Z, Wang H, Jiang Y, Hartnett ME (2014) VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis. Am J Pathol. \n                    https:\/\/doi.org\/10.1016\/j.ajpath.2013.12.023","journal-title":"Am J Pathol"},{"issue":"7","key":"9618_CR27","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1167\/iovs.08-3256","volume":"50","author":"G Byfield","year":"2009","unstructured":"Byfield G, Budd S, Hartnett ME (2009) The role of supplemental oxygen and JAK\/STAT signaling in intravitreous neovascularization in a ROP rat model. Invest Ophthalmol Vis Sci 50(7):3360\u20133365. \n                    https:\/\/doi.org\/10.1167\/iovs.08-3256","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"9618_CR28","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.exer.2009.06.011","volume":"89","author":"S Budd","year":"2009","unstructured":"Budd S, Byfield G, Martiniuk D, Geisen P, Hartnett ME (2009) Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP. Exp Eye Res 89(5):718\u2013727","journal-title":"Exp Eye Res"},{"issue":"2","key":"9618_CR29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1167\/iovs.13-13429","volume":"55","author":"H Wang","year":"2014","unstructured":"Wang H, Yang Z, Jiang Y, Flannery J, Hammond S, Kafri T, Vemuri SK, Jones B, Hartnett ME (2014) Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 55(2):737\u2013744. \n                    https:\/\/doi.org\/10.1167\/iovs.13-13429","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"9618_CR30","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1167\/iovs.08-1780","volume":"49","author":"ME Hartnett","year":"2008","unstructured":"Hartnett ME, Martiniuk D, Byfield G, Geisen P, Zeng G, Bautch VL (2008) Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in rat model of ROP: relevance to plus disease. Invest Ophthalmol Vis Sci 49(7):3107\u20133114","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9618_CR31","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1523\/JNEUROSCI.15-07-04738.1995","volume":"15","author":"J Stone","year":"1995","unstructured":"Stone J, Itin A, Alon T, Peer J, Gnessin H, Chan-Ling T, Keshet E (1995) Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 15:4738\u20134747","journal-title":"J Neurosci"},{"issue":"4","key":"9618_CR32","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood-2006-07-037952","volume":"109","author":"G Zeng","year":"2007","unstructured":"Zeng G, Taylor SM, McColm JR, Kappas NC, Kearney JB, Williams LH, Hartnett ME, Bautch VL (2007) Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. Blood 109(4):1345\u20131352","journal-title":"Blood"},{"issue":"7","key":"9618_CR33","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1167\/iovs.10-6798","volume":"52","author":"GA Lutty","year":"2011","unstructured":"Lutty GA, McLeod DS, Bhutto I, Wiegand SJ (2011) Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Invest Ophthalmol Vis Sci 52(7):4039\u20134047","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"9618_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","volume":"171","author":"K Nishijima","year":"2007","unstructured":"Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171(1):53\u201367","journal-title":"Am J Pathol"},{"issue":"12","key":"9618_CR35","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1172\/JCI200317977","volume":"111","author":"Y Sun","year":"2003","unstructured":"Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, Greenberg DA (2003) VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 111(12):1843","journal-title":"J Clin Invest"},{"issue":"9","key":"9618_CR36","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/bies.20092","volume":"26","author":"E Storkebaum","year":"2004","unstructured":"Storkebaum E, Lambrechts D, Carmeliet P (2004) VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 26(9):943\u2013954","journal-title":"Bioessays"},{"issue":"4","key":"9618_CR37","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.ajpath.2012.12.032","volume":"182","author":"RH Foxton","year":"2013","unstructured":"Foxton RH, Finkelstein A, Vijay S, Dahlmann-Noor A, Khaw PT, Morgan JE, Shima DT, Ng YS (2013) VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol 182(4):1379\u20131390. \n                    https:\/\/doi.org\/10.1016\/j.ajpath.2012.12.032","journal-title":"Am J Pathol"}],"updated-by":[{"DOI":"10.1007\/s10456-018-9626-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000}}],"container-title":["Angiogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10456-018-9618-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-018-9618-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-018-9618-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T23:56:59Z","timestamp":1589414219000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10456-018-9618-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,5]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["9618"],"URL":"https:\/\/doi.org\/10.1007\/s10456-018-9618-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10456-018-9626-5","asserted-by":"object"}]},"ISSN":["0969-6970","1573-7209"],"issn-type":[{"value":"0969-6970","type":"print"},{"value":"1573-7209","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,5]]},"assertion":[{"value":"9 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article \u201cGene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy\u201d, written by \u201cAaron B. Simmons, Colin A. Bretz, Haibo Wang, Eric Kunz, Kassem Hajj, Carson Kennedy, Zhihong Yang, Thipparat Suwanmanee, Tal Kafri and M. Elizabeth Hartnett\u201d, was originally published electronically on the publisher\u2019s internet portal (currently SpringerLink) on 05 May 2018 without open access. With the author(s)\u2019 decision to opt for Open Choice the copyright of the article changed on 20 June 2018 to \u00a9 The Author(s) 2018 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}